Sumitomo Mitsui Trust Group
NTLA icon

Sumitomo Mitsui Trust Group’s Intellia Therapeutics NTLA Stock Holding History

Sumitomo Mitsui Trust Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$43.5M Buy
3,605,623
+708,094
+24% +$8.85M 0.02% 474
2026
Q2 		$49M Buy
2,897,529
+924,468
+47% +$12.9M 0.03% 461
2026
Q1 		$25.3M Sell
1,973,061
-219,400
-10% -$2.79M 0.02% 591
2025
Q4 		$19.7M Sell
2,192,461
-162,395
-7% -$2.24M 0.01% 639
2025
Q3 		$40.7M Sell
2,354,856
-316,409
-12% -$3.9M 0.02% 523
2025
Q2 		$25.1M Sell
2,671,265
-154,096
-5% -$1.27M 0.02% 613
2025
Q1 		$20.1M Sell
2,825,361
-167,302
-6% -$1.69M 0.01% 638
2024
Q4 		$34.9M Sell
2,992,663
-156,736
-5% -$2.45M 0.02% 543
2024
Q3 		$64.7M Sell
3,149,399
-108,290
-3% -$2.5M 0.04% 385
2024
Q2 		$72.9M Sell
3,257,689
-141,629
-4% -$3.37M 0.05% 344
2024
Q1 		$93.5M Sell
3,399,318
-79,244
-2% -$2.2M 0.06% 316
2023
Q4 		$106M Sell
3,478,562
-41,733
-1% -$1.2M 0.08% 269
2023
Q3 		$111M Buy
3,520,295
+125,639
+4% +$4.87M 0.09% 228
2023
Q2 		$138M Buy
3,394,656
+281,692
+9% +$11.4M 0.11% 190
2023
Q1 		$116M Buy
3,112,964
+136,962
+5% +$5.37M 0.09% 253
2022
Q4 		$104M Buy
2,976,002
+12,074
+0.4% +$574K 0.08% 280
2022
Q3 		$166M Buy
2,963,928
+182,792
+7% +$11.3M 0.14% 169
2022
Q2 		$144M Sell
2,781,136
-91,133
-3% -$4.63M 0.11% 207
2022
Q1 		$209M Buy
2,872,269
+118,366
+4% +$10M 0.14% 154
2021
Q4 		$326M Buy
2,753,903
+353,970
+15% +$44.3M 0.2% 112
2021
Q3 		$322M Sell
2,399,933
-727,670
-23% -$110M 0.2% 109
2021
Q2 		$506M Sell
3,127,603
-1,679,691
-35% -$131M 0.3% 74
2021
Q1 		$386M Sell
4,807,294
-297,068
-6% -$19.9M 0.24% 90
2020
Q4 		$278M Sell
5,104,362
-958,154
-16% -$34.8M 0.18% 128
2020
Q3 		$121M Sell
6,062,516
-132,673
-2% -$2.77M 0.08% 261
2020
Q2 		$130M Sell
6,195,189
-896,074
-13% -$15.2M 0.09% 234
2020
Q1 		$86.7M Sell
7,091,263
-87,257
-1% -$1.18M 0.07% 287
2019
Q4 		$105M Sell
7,178,520
-61,217
-0.8% -$852K 0.08% 255
2019
Q3 		$96.6M Buy
7,239,737
+5,023,077
+227% +$80.1M 0.08% 256
2019
Q2 		$36.3M Buy
2,216,660
+1,169,968
+112% +$18.4M 0.03% 533
2019
Q1 		$17.9M Buy
+1,046,692
New +$15.6M 0.02% 650

Other funds holding NTLA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals Tarrytown, New York $180M AUM 18.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Contrarius Group Holdings
Contrarius Group Holdings Hamilton, Bermuda $2.05B AUM 66.09% 1-Year Est. Return
Jupiter Asset Management
Jupiter Asset Management London, United Kingdom $21.4B AUM 19.74% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $57.2B AUM 42.49% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Sumitomo Mitsui Trust Group's NTLA Position: Q3 2026 in Review

Sumitomo Mitsui Trust Group increased its Intellia Therapeutics (NTLA) stake by 24% in Q3 2026, buying an estimated $8.85M and bringing the position to 3,605,623 shares worth $43.5M. The position accounts for 0.02% of the portfolio, ranked #474.

Sumitomo Mitsui Trust Group first reported a position in NTLA in Q1 2019 and has held it in 31 quarters since. The position peaked at $506M in Q2 2021. 156 funds tracked by Wall St. Rank hold NTLA as of Q3 2026.

  • Sumitomo Mitsui Trust Group held 3,605,623 shares of Intellia Therapeutics worth $43.5M as of Q3 2026.
  • Sumitomo Mitsui Trust Group bought 708,094 Intellia Therapeutics shares in Q3 2026, an estimated $8.85M.
  • Intellia Therapeutics made up 0.02% of Sumitomo Mitsui Trust Group's portfolio in Q3 2026, its #474 holding.
  • Sumitomo Mitsui Trust Group first reported a position in Intellia Therapeutics in Q1 2019 and has held it in 31 quarters since.
  • Sumitomo Mitsui Trust Group's Intellia Therapeutics position peaked at $506M in Q2 2021.
  • 156 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2026.

Based on Sumitomo Mitsui Trust Group's 13F filing for Q3 2026, filed 29 Oct 2026.